GlassScriptPhysician profile
William H Hawkins
NPI 1154310555
$3,572.08
in general payments reported to CMS, 2019-2025
21 companies · $315 in 2025
The $315 reported for 2025 was less than what a typical Otolaryngology provider received nationally (typical 2025 total: $317).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $416 · 2020: $481 · 2021: $742 · 2022: $444 · 2023: $589 · 2024: $586 · 2025: $315.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,456 · Education: $34.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,455.72 |
| Education | $34.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $711.96 | 2022-2025 | |
| Regeneron Healthcare Solutions, INC. | $692.08 | 2019-2025 | Dupixent |
| Intersect Ent, INC. | $655.18 | 2020-2022 | |
| Optinose US, INC. | $335.18 | 2019-2025 | |
| Arbor Pharmaceuticals, INC. | $218.69 | 2019 | |
| Stryker Corporation | $169.80 | 2019-2023 | Audion Et Dilation System |
| Medtronic, INC. | $165.20 | 2023-2024 | Propel, Nim Vital, Mazor X System |
| Aerin Medical INC. | $126.32 | 2021-2023 | |
| Sanofi-Aventis U.S. LLC | $118.20 | 2021 | |
| Glaxosmithkline, LLC. | $84.33 | 2022-2023 | Nucala |
| Novartis Pharmaceuticals Corporation | $62.43 | 2019 | |
| Kls-Martin L.P. | $46.02 | 2022 | |
| Merck Sharp & Dohme LLC | $34.03 | 2021-2023 | |
| Amgen INC. | $34.00 | 2025 | |
| Integra Lifesciences Corporation | $33.94 | 2024 | Relieva Spinplus Nav, Trudi Probe, Inspira Air |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neurent Medical Limited | $29.86 | 2024 | Neuromark Radiofrequency Console, Neuromark Device |
| Acclarent, INC | $19.64 | 2023 | Trudi Nav Cable, Acclarent Aera |
| Alk-Abello, INC | $18.10 | 2021 | |
| Phathom Pharmaceuticals, INC. | $17.12 | 2025 | Voquezna |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Hawkins listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.